Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
31 January, 2015 22:35 IST
Lupin can garner sales of USD 30 mn from generic Yasmin: Angel Broking
Source: IRIS Exclusive | 20 Dec, 2012, 01.20PM
Comments  |  Post Comment

Angel Broking has maintained 'Buy' on Lupin with a price target of Rs 655 in its report dated Dec. 20, 2012.

Pharma major, Lupin, announced that its subsidiary Lupin Pharmaceuticals has received final approval for its Drospirenone and Ethinyl Estradiol Tablets, 3 mg / 0.03 mg from the United States Food and Drugs Administration (FDA) to market a generic version of BayerHealthcare's (Bayer) Yasmin Tablets 3 mg / 0.03 mg.

Lupin's Drospirenone and Ethinyl Estradiol Tablets are the AB rated generic equivalent of Bayer's Yasmin Tablets 3 mg /0.03 mg. Yasmin Tablets had annual US sales of approximately USD 275 million (IMS MAT Sept 2012 sales). On a conservative side the company can garner sales of around USD 30 million and net profit of USD 9-10 million.

Click here to view full report


Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
By: Carol | 28 December 2012 Reply | Forward | Report Abuse 
Yasmin might have generated lots of sales, but that has more to do with heavy advertising than the quality of the pill itself. In fact, the FDA says that there might be a significantly higher chance that woman who take birth control pills with drospirenone, such as Yaz, Yasmin and Ocella, will experience a blood clot. http://www.publichealthwatchdog.com/fda-study-links-yaz-yasmin-and-other-similar-birth-control-pills-to-increased-risk-of-blood-clots/
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Whirlpool of India standalone quarterly earnings surge 48.42% - 30-Jan-2015 19:19
Shriram Transport Finance board elevates Lakshminarayanan as chairman - 30-Jan-2015 17:26
Tech Mahindra consolidated quarterly profit declines 20.25% - 30-Jan-2015 15:49
Binani Industries swings to profit in Oct-Dec quarter - 30-Jan-2015 15:43
NTPC standalone quarterly net climbs 7.43% - 30-Jan-2015 15:38
Kirloskar Brothers swings to loss in Oct-Dec quarter - 30-Jan-2015 15:35
Adani Enterprises consolidated quarterly profit soars 6.51 times - 30-Jan-2015 15:30
JSW Steel consolidated quarterly profit drops 29.49% - 30-Jan-2015 15:25
Monsanto India standalone quarterly net drops 25.76% - 30-Jan-2015 15:20
Dabur India consolidated Q3 profit climbs 16.5% - 30-Jan-2015 14:55
Siemens Q1 profit surges to Rs 6.34 bn - 30-Jan-2015 14:47
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer